Developer of T cell therapeutics designed to cure autoimmune and degenerative diseases.
Developer of T cell therapeutics designed to cure autoimmune and degenerative diseases.
Drug Discovery📍 San Francisco, CAFounded 2019
Current Valuation
$715M
as of 2023-Q1
PRIVATE
QL Price
$715M
0% vs last round
QuantLogix's current estimate for Sonoma Biotherapeutics, published 2026-09-27 — in line with the last disclosed round of $715M (2023-Q1).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$715M
2023-Q1
weight 0.09
How this price has held up
No round has priced for Sonoma Biotherapeutics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Sonoma Biotherapeutics, 2026-09-27 (6148f435e18755e6).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Sonoma Biotherapeutics going public?
No. Sonoma Biotherapeutics is private and has not filed to go public. There is no S-1 on file.
What is Sonoma Biotherapeutics' valuation in 2026?
Sonoma Biotherapeutics is valued at $715M as of 2023-Q1, set by its Series B1 ($30M, Mar 2023). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Sonoma Biotherapeutics filed an S-1?
No public S-1 is on file for Sonoma Biotherapeutics.
How much has Sonoma Biotherapeutics raised?
Sonoma Biotherapeutics has raised $365.1M in total, most recently a Series B1 of $30M in Mar 2023.
Is Sonoma Biotherapeutics publicly traded — can you buy Sonoma Biotherapeutics stock?
No. Sonoma Biotherapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Sonoma Biotherapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2019
HQ
San Francisco, CA
Employees
112
Total Raised
$365.1M
Last Round
Series B1 — $30M (Mar 2023)
IPO Status
private
Fundraising Status
Series B1 · $30M · 3y 6mo ago
privateTotal raised $365.1M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series B1
$30M
Mar 2023
—
$715M
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
4
3 active · 2 recruiting
Lead phase
Phase 1
most advanced registered study
Focus areas
Safety
Hidradenitis Suppurativa · Rheumatoid Arthritis
Latest trial start
2025-07-22
Name-verified against lead sponsor "Sonoma Biotherapeutics, Inc." on ClinicalTrials.gov as of 2026-09-19. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
11
via careers page
Product-build share
55%
engineering, research, product, design
Trajectory
steady
product-led hiring — 55% of open roles build product; the rest are go-to-market and G&A.
Counted from Sonoma Biotherapeutics's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
BiotechnologyLife ScienceTherapeutics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2023-Q1. Refreshed quarterly.